New Food and Drug Administration regulations to control seasonal drug releases
The Saudi Food and Drug Authority (SFDA) has announced the release of the second draft of its regulations and requirements for releasing products under its control for use in exhibitions, conferences, and seasonal events. This update aims to streamline procedures and improve the release mechanisms for medicines, pharmaceuticals, and herbal products, ensuring the safety of products entering the Kingdom during major events, religious seasons, and entertainment festivals, while also simplifying operational steps for importers and exhibitors.
Legislative and historical framework for medical product regulation
The Saudi Food and Drug Authority (SFDA) bases its decisions and ongoing updates on its statute, issued by Royal Decree No. M/6 dated 25 Muharram 1428 AH. Since its establishment, the SFDA has consistently developed its regulatory systems to ensure the safety of food, drugs, medical devices, and cosmetics. These recent updates are part of the Kingdom's digital and regulatory transformation strategy, as the SFDA continuously reviews and updates its executive regulations to keep pace with rapid global developments in the healthcare and pharmaceutical industries, while ensuring procedural flexibility without compromising stringent health standards.
Unified undertaking form and facilitating drug clearance procedures
The draft of the updated version reveals the introduction of precise and specific requirements for regulating imports for exhibition or marketing purposes. Among the most significant amendments is the elimination of the previous procedure, which required submitting a separate declaration to customs stating that the goods would not be consumed or marketed, along with providing a copy to the relevant authority and re-exporting them after the event. This complex procedure has been replaced by consolidating all requirements into a single, independent "Declaration" form specifically designed for the clearance of medicines and pharmaceutical products. This new form covers all import purposes, thereby reducing the time and effort required by international and local companies participating in medical and scientific exhibitions and events within the Kingdom.
Local and international dimensions of new pharmaceutical regulations
This regulatory step carries significant implications both locally and internationally. Locally, these facilitations contribute to supporting the Kingdom's rapidly growing medical exhibitions and conferences sector, in line with Saudi Vision 2030. Furthermore, rigorous oversight ensures the protection of consumers and patients from any substandard products. Regionally and internationally, streamlining drug clearance enhances the Kingdom's attractiveness as a prime destination for major international companies to showcase their latest medical and therapeutic innovations at international events and conferences, thus solidifying Saudi Arabia's position as a leading regional hub for healthcare and pharmaceutical investment.
